Ishita Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE806D01016
  • NSEID:
  • BSEID: 524400
INR
74.01
-4.49 (-5.72%)
BSENSE

Nov 20

BSE+NSE Vol: 445

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "74.01",
    "chg": -4.49,
    "chgp": "-5.72%",
    "dir": -1,
    "prev_price": "78.50",
    "mcapval": "23.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE806D01016",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "445 ",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ishita Drugs Falls 3.14%: Valuation Concerns and Margin Pressures Shape the Week",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-falls-314-valuation-concerns-and-margin-pressures-shape-the-week-4255870",
        "imagepath": "",
        "date": "2026-11-07 17:07:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> Stock opens at Rs.72.00 amid Sensex rally</p>\n                    <p><strong>5 Nov:</strong> Q2 FY27 results reveal margin pressures; stock surges 8.32%</p>\n                    <p><strong>6 Nov:</strong> Valuation shift signals price attractiveness erosion; stock falls 8.96%</p>\n                    <p><strong>6 Nov:</strong> Week closes at Rs.71.00, down 3.14% vs Sensex +7.15%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.72.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"sta..."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4243846",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/IshitaDrugsIndu_valuationdot_4243846.png",
        "date": "2026-10-30 08:01:15",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Strong Sell. This repositioning in price-to-earnings and price-to-book value metrics offers investors a nuanced perspective on the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs Falls 4.34%: 2 Key Factors Driving the Weekly Decline",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-falls-434-2-key-factors-driving-the-weekly-decline-4228938",
        "imagepath": "",
        "date": "2026-10-17 17:05:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>12 Oct:</strong> Stock opens steady at Rs.76.00 amid weak Sensex</p>\n                    <p><strong>13 Oct:</strong> Downgrade to Strong Sell announced, stock falls 1.45%</p>\n                    <p><strong>15 Oct:</strong> Stock rebounds 2.80% to Rs.77.00 on low volume</p>\n                    <p><strong>16 Oct:</strong> Valuation shift to fair grade, stock drops 5.58%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.76.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.72.70</div><d..."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-changing-price-attractiveness-4227045",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/IshitaDrugsIndu_valuationdot_4227045.png",
        "date": "2026-10-16 08:00:32",
        "description": "Ishita Drugs & Industries Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting evolving market perceptions and sector dynamics. Despite a recent day gain of 2.80%, the micro-cap pharmaceutical company faces valuation challenges when compared to its peers, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a more tempered price attractiveness."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-4224994",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/IshitaDrugsIndu_mojoScore_4224994.png",
        "date": "2026-10-14 08:15:30",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 13 Oct 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The micro-cap pharmaceutical company’s recent performance and valuation metrics have raised concerns among analysts, prompting a reassessment of its outlook across quality, valuation, financial trend, and technical parameters."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-changing-price-attractiveness-4206667",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/IshitaDrugsIndu_valuationdot_4206667.png",
        "date": "2026-09-28 08:00:32",
        "description": "Ishita Drugs & Industries Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial performance. Despite a recent uptick in share price, the company’s micro-cap status and relative valuation metrics warrant a cautious approach for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4195481",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/IshitaDrugsIndu_valuationdot_4195481.png",
        "date": "2026-09-17 08:00:34",
        "description": "Ishita Drugs & Industries Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a challenging market environment reflected in a 5.08% drop in share price on 17 Sep 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4178364",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/IshitaDrugsIndu_valuationdot_4178364.png",
        "date": "2026-09-02 08:00:40",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by a recalibration of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This development comes amid a challenging pharmaceutical sector landscape and a micro-cap status that continues to influence investor sentiment. A detailed analysis of these valuation changes against historical and peer benchmarks reveals a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology space."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-renewed-price-attractiveness-4170738",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/IshitaDrugsIndu_valuationdot_4170738.png",
        "date": "2026-08-27 08:00:34",
        "description": "Ishita Drugs & Industries Ltd has recently seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite a modest decline in share price and a challenging sector backdrop, the company’s improved price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers suggest a compelling entry point for investors seeking value in the pharmaceuticals and biotechnology micro-cap space."
      }
    ],
    "total": 27,
    "sid": "444125",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Outcome Of Board Meeting Held On 03Rd November 2026",
      "datetime": "03-Nov-2026",
      "details": "Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 alongwith limited review report issued by the statutory auditors of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 03Rd November 2026",
      "datetime": "03-Nov-2026",
      "details": "Board of Directors of Ishita Drugs and Industries Limited at its meeting held today i.e. Tuesday 03rd November 2026 have 1. Approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 along with the Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Discussed the upgradation project of manufacturing facility for compliance with Revised Schedule M.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter Ended 30Th September 2026",
      "datetime": "28-Oct-2026",
      "details": "Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Outcome Of Board Meeting Held On 03Rd November 2026

03-Nov-2026 | Source : BSE

Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 alongwith limited review report issued by the statutory auditors of the Company.

Board Meeting Outcome for Outcome Of Board Meeting Held On 03Rd November 2026

03-Nov-2026 | Source : BSE

Board of Directors of Ishita Drugs and Industries Limited at its meeting held today i.e. Tuesday 03rd November 2026 have 1. Approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 along with the Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Discussed the upgradation project of manufacturing facility for compliance with Revised Schedule M.

Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter Ended 30Th September 2026

28-Oct-2026 | Source : BSE

Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available